Select Bibliography

Filter by any of these (after searching):

Laplant, B.

AUTHOR ABSTRACT DEADLINES

A meeting abstract must be submitted by the first or corresponding author to the Alliance Publications Coordinator (publications@AllianceNCTN.org) at least two weeks prior to the meeting abstract submission deadline. For detailed information about Alliance Publications guidelines, please refer to the policies, along with the author abstract deadlines.

There are 7 items

N0436: A phase II trial of irinotecan plus cetuximab in patients with metastatic breast cancer and prior anthracycline and/or taxane-containing therapy

Hobday, T. J. , Stella, P. J. , Fitch, T. R. , Jaslowski, A. ... - ASCO - J Clin Oncol - 2008

Abstract - Primary - Primary - Breast - NCCTG-N0436

Phase I Trial of Rituximab, Cladribine and Temsirolimus (RCT) for Initial Therapy of Mantle Cell Lymphoma

Inwards, D. J. , Fishkin, P. , Laplant, B. R. , Drake, M. T. ... - ASH - ASH Annual Meeting Abstracts - 2012

Abstract - Primary - Primary - Lymphoma - NCCTG-N078D

A correlative study of cardiac biomarkers and left ventricular ejection fraction (LVEF) from N9831, a phase III randomized trial of chemotherapy and trastuzumab as adjuvant therapy for HER2 positive breast cancer

Kutteh, L.A.. , Hobday, T. J. , Jaffe, A. S. , Laplant, B. R. ... - ASCO - J Clin Oncol - 2007

Abstract - Secondary - Primary - Breast - NCCTG-N9831

Cytokeratin-19 (CK19) and mammaglobin (MGB1) gene expression in circulating tumor cells (CTCs) from metastatic breast cancer patients enrolled in the NCCTG trials, N0436 and N0437

Reinholz, M. , Kitzmann, K. , Hobday, T. , Northfelt, D. , Laplant, B. ... - ASCO - J Clin Oncol - 2009

Abstract - Secondary-not-in-original - Comprehensive - Breast - NCCTG-N0436 , NCCTG-N0437

Circulating tumor cells in North Central Cancer Treatment Group breast clinical trials

Reinholz, M. , Kitzmann, K. , Tenner, K. , Hillman, D. , Hobday, T. ... - ISMRC - 7th International Symposium on Minimal Residual Cancer - 2009

Abstract - Secondary-not-in-original - Comprehensive - Breast - NCCTG-N0234 , NCCTG-N0336 , NCCTG-N0338 , NCCTG-N0436 , NCCTG-N0437

Phase II trial of weekly nab (nanoparticle albumin-bound)-paclitaxel (nab-paclitaxel) (Abraxane®) in combination with gemcitabine in patients with metastatic breast cancer (N0531)

Roy, V. , LaPlant, B. R. , Gross, G. G. , Bane, C. L. ... - - Ann Oncol - 2009

Manuscript - Primary - Primary - Breast - NCCTG-0531

NCCTG phase II trial N0531of weekly nab-paclitaxel (nab-p) in combination with gemcitabine (gem) in patients with metastatic breast cancer (MBC)

Roy, V. , Laplant, B. , Gross, G. , Palmieri, F. ... - - J Clin Oncol - 2007

Abstract - Primary - Primary - Breast - NCCTG-N0531